Seminars in Oncology
Volume 34 , Pages S10-S16 , April 2007

New Generation of Molecular Prognostic and Predictive Tests for Breast Cancer

  • Lajos Pusztai

      Affiliations

    • Dr Pusztai owns stock in Nuvera Biosciences Inc, and has served as a consultant to Bristol-Myers Squibb Company and Roche Pharmaceuticals.
    • Corresponding Author InformationAddress reprint requests to Lajos Pusztai, MD, PhD, The University of Texas, M. D. Anderson Cancer Center, Department of Breast Medical Oncology, Unit 1354, PO Box 301439, Houston, TX 77230-1439
    • ,
  • Massimo Cristofanilli
    • ,
  • Soonmyung Paik

References 

  1. Ravdin PM, Siminoff IA, Harvey JA. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol. 1998;16:515–521
  2. Bast RC, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865–1878
  3. van ’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536
  4. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009
  5. Buyse M, Loi S, van’t Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006;98:1183–1192
  6. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365:671–679
  7. Foekens JA, Atkins D, Zhang Y, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol. 2006;24:1665–1671
  8. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000;18:3748–3757
  9. Rhodes A, Jasani B, Barnes DM, et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000;53:125–130
  10. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–2826
  11. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006;8:R25
  12. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–3734
  13. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–2685
  14. M. D. Anderson Cancer Center: Chemotherapy Response Calculators. Available at: http://www.mdanderson.org/care_centers/breastcenter/dIndex.cfm?pn=448442B2-3EA5-4BAC-98310076A9553E63 (accessed November 1, 2006)
  15. Rouzier R, Pusztai L, Delaloge S, et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 2005;23:8331–8339
  16. Di Leo A, Isola J. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: Are we at the end of the beginning?. Clin Breast Cancer. 2003;4:179–186
  17. Pusztai L, Gianni L. Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancer. Nat Clin Pract Oncol. 2004;1:44–50
  18. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006;24:4236–4244
  19. Ashworth T. A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Med J Aust. 1869;14:146
  20. Kagan M, Howard D, Bendele T, et al. A sample preparation and analysis system for identification of circulating tumor cells. J Clin Ligand Assay. 2002;25:104–110
  21. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–791
  22. Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol. 2006;33(suppl):S9–S14
  23. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005;23:1420–1430
  24. Kattan MW. Evaluating a new marker’s predictive contribution. Clin Cancer Res. 2004;10:822–824
  25. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol. 2005;23:7332–7341
  26. US Food and Drug Administration. Center for Devices and Radiologic Health homepage. Available at: www.fda.gov/cdrh (accessed November 1, 2006)
  27. US Food and Drug Administration. Draft guidance for industry, clinical laboratories, and FDA staff on in vitro diagnostic multivariate index assays; Availability. Available at: www.fda.gov/OHRMS/DOCKETS/98fr/ch0641.pdf (accessed November 1, 2006)

PII: S0093-7754(07)00069-3

doi: 10.1053/j.seminoncol.2007.03.015

Seminars in Oncology
Volume 34 , Pages S10-S16 , April 2007

Article Tools

* Image Usage & Resolution